Exelixis/$EXEL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Exelixis
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Ticker
$EXEL
Sector
Primary listing
Employees
1,147
Headquarters
Website
Exelixis Metrics
BasicAdvanced
$11B
18.85
$2.08
0.28
-
Price and volume
Market cap
$11B
Beta
0.28
52-week high
$49.62
52-week low
$25.17
Average daily volume
2.6M
Financial strength
Current ratio
3.513
Quick ratio
3.265
Long term debt to equity
8.844
Total debt to equity
8.844
Profitability
EBITDA (TTM)
781.521
Gross margin (TTM)
96.59%
Net profit margin (TTM)
27.01%
Operating margin (TTM)
33.71%
Effective tax rate (TTM)
22.35%
Revenue per employee (TTM)
$1,940,000
Management effectiveness
Return on assets (TTM)
17.24%
Return on equity (TTM)
29.00%
Valuation
Price to earnings (TTM)
18.853
Price to revenue (TTM)
4.922
Price to book
5.2
Price to tangible book (TTM)
5.37
Price to free cash flow (TTM)
15.186
Free cash flow yield (TTM)
6.58%
Free cash flow per share (TTM)
2.578
Growth
Revenue change (TTM)
10.73%
Earnings per share change (TTM)
81.76%
3-year revenue growth (CAGR)
12.77%
10-year revenue growth (CAGR)
53.34%
3-year earnings per share growth (CAGR)
34.69%
10-year earnings per share growth (CAGR)
7.61%
What the Analysts think about Exelixis
Analyst ratings (Buy, Hold, Sell) for Exelixis stock.
Bulls say / Bears say
Net product revenues in Q2 2025 jumped 18.8% year over year to $520.0 million, driven by increased Cabometyx sales volume, demonstrating strong commercial momentum (Nasdaq).
The U.S. FDA approved Cabometyx for previously treated advanced pancreatic and extra-pancreatic neuroendocrine tumors in March 2025, broadening the drug’s indications and expanding the addressable market (Business Wire).
STELLAR-303 phase 3 topline results showed a statistically significant overall survival benefit for zanzalintinib combined with atezolizumab versus regorafenib in metastatic colorectal cancer, marking the first pivotal success for the zanzalintinib program and unlocking a new potential revenue stream (Business Wire)
Total revenues fell 10.8% year over year in Q2 2025 to $568.3 million due to a 75.9% drop in collaboration revenues after a one-time $150 million milestone lapsed, underscoring volatile non-product revenue streams (Business Wire).
The COSMIC-313 trial combining Cabometyx with Opdivo and Yervoy failed to improve overall survival in first-line advanced renal cell carcinoma, halting a potential label expansion and reflecting pipeline execution risk (Fierce Pharma).
Overreliance on Cabometyx is evident as COMETRIQ contributed only $2.1 million of net product revenues in Q2 2025, highlighting limited diversification of revenue sources (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2025.
Exelixis Financial Performance
Revenues and expenses
Exelixis Earnings Performance
Company profitability
Exelixis News
AllArticlesVideos
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm
Business Wire2 weeks ago
Exelixis Announces Appointment of Dana T. Aftab, Ph.D.
Business Wire2 weeks ago
Analyst Surprised By Exelixis Q2 Revenue Miss, Delays STELLAR-304 Readout, Halts STELLAR-305 Phase 3 Plans
Benzinga2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Exelixis stock?
Exelixis (EXEL) has a market cap of $11B as of September 15, 2025.
What is the P/E ratio for Exelixis stock?
The price to earnings (P/E) ratio for Exelixis (EXEL) stock is 18.85 as of September 15, 2025.
Does Exelixis stock pay dividends?
No, Exelixis (EXEL) stock does not pay dividends to its shareholders as of September 15, 2025.
When is the next Exelixis dividend payment date?
Exelixis (EXEL) stock does not pay dividends to its shareholders.
What is the beta indicator for Exelixis?
Exelixis (EXEL) has a beta rating of 0.28. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.